1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
1 LA Begley, S Kasina, J MacDonald, JA Macoska. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008;43:194-199 Crossref
2 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
3 M Paubert-Braquet, JM Mencia Huerta, H Cousse, P Braquet. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304 Crossref
4 R Vela Navarrete, JV Garcia Cardoso, A Barat, F Manzarbeitia, A López Farré. BPH and inflammation: pharmacological effects of Permixon® on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549-555 Crossref
5 S Bernichtein, N Pigat, P Camparo, et al. Anti-inflammatory properties of lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate. 2015;75:706-722 Crossref
6 A Ragab, JMF Ragab-Thomas, A Delhan. Effects of Permixon® (Serepro-stat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. F Di Silverio, A Steg (Eds.) New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis (Acta Medica, Rome, Italy, 1998) 293-296
7 A Latil, Y Verscheure, J Tisné-Versailles, T N'Guyen. Permixon lipidosterolic extract of Serenoa repens modifies prostate inflammation status. Eur Urol Suppl. 2009;8:208 Crossref
8 A Latil, F Lantoine-Adam, L Aguilar, T N'Guyen. Anti-inflammatory properties of Permixon lipidosterolic extract of Serenoa repens: in vitro and in vivo results. Eur Urol Suppl. 2010;9:209 Crossref
9 A Latil, C Libon, M Templier, D Junquero, F Lantoine-Adam, T Nguyen. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:E301-E307 Crossref
10 N Sirab, G Robert, V Fasolo, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013;14:14301-14320 Crossref
11 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa Repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
12 G Pace, C Di Massimo, D De Amicis, C Vicentini, MG Ciancarelli. Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol. 2011;37:617-622 Crossref
13 G Penna, B Fibbi, S Amuchastegui, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056-4064 Crossref
14 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
15 A Siejka, AV Schally, NL Block, N Barabutis. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int. 2010;106:1382-1388Crossref
16 C Stephan, C Xu, DA Brown, et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate. 2006;66:651-659 Crossref
17 M Tagaya, M Oka, M Ueda, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: a genome-wide DNA microarray analysis. Cytokine. 2009;47:185-193 Crossref
18 G Theyer, G Kramer, I Assmann, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992;66:96-107
19 Y Fan, S Hu, J Liu, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators Inflamm. 2014;2014:397815
20 F Yu, Y Lin, T Zhan, L Chen, S Guo. HGF expression induced by HIF-1α promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol Int. 2015;39:310-317 Crossref
21 CG Roehrborn, P Siami, J Barkin, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123-131 Crossref
22 Hu S, Cui Y, Fan Y, et al. The role of macrophage migration inhibitory factor on the effect of BPH cells: modulation COX-2 and p53 signaling [poster 793]. Presented at: European Association of Urology congress; 20–24 March 2015; Madrid, Spain.
